N-庚基羟胺 | 2912-94-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N-庚基羟胺
• 英文名称: N-heptyl hydroxylamine
• 英文别名: N-heptylhydroxylamine
• CAS: 2912-94-9
• 化学式: C₇H₁₇NO
• 分子量: 131.218
• InChiKey: OTGVQQOBOHJFJE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  9
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-庚基羟胺 在 sodium hydroxide 作用下， 以 乙醇 、 氯仿 为溶剂， 反应 24.0h， 生成 S-(N-heptyl-N-hydroxycarbamoyl)glutathione
  参考文献：
  名称：

  Role of Hydrophobic Interactions in Binding S-(N-Aryl/Alkyl-N-hydroxy- carbamoyl)glutathiones to the Active Site of the Antitumor Target Enzyme Glyoxalase I

  摘要：

  Hydrophobic interactions play an important role in binding S-(N-aryl/alkyl-N-hydroxycarbamoyl)glutathiones to the active sites of human, yeast, and Pseudomonas putida glyoxalase I, as the log K-i values for these mechanism-based competitive inhibitors decrease linearly with increasing values of the hydrophobicity constants (pi) of the N-aryl/alkyl substituents. Hydrophobic interactions also help to optimize polar interactions between the enzyme and the glutathione derivatives, given that the K-i value for S-(N-hydroxycarbamoyl)glutathione (pi = 0) with the human enzyme is 35-fold larger than the interpolated value for this compound obtained from the log K-i versus pi plot. Computational studies, in combination with published X-ray crystallographic measurements, indicate that human glyoxalase I binds the syn-conformer of S-(N-aryl-N-hydroxycarbamoyl)glutathione in which the N-aryl substituents are in their lowest-energy conformations. These studies provide both an experimental and a conceptual framework for developing better inhibitors of this antitumor target enzyme.

  DOI：

  10.1021/jm000160l
• 作为产物：
  描述：

  正庚醛肟 在 盐酸 、 sodium cyanoborohydride 作用下， 以 甲醇 为溶剂， 生成 N-庚基羟胺
  参考文献：
  名称：

  氰氢硼酸盐阴离子作为选择性还原剂

  摘要：

  氰基氢化硼酸钠 (NaBH3CN) 以显着的选择性还原各种有机官能团。醛和酮的还原依赖于 pH，反应在 pH 3-4 下很容易进行。在酸催化下，肟 a 顺利还原为烷基羟胺，烯胺还原为胺。在 BHaCN 存在下，醛或酮与氨、伯胺或仲胺在 H -7 处的反应分别导致伯胺、仲胺或叔胺，以及羰基的还原胺化。取代丙酮酸与氨和 BH3CN 的反应提供了一种合成氨基酸的极好方法；15N 标记可以通过使用 I5NH3 来完成。BHICN 的氢可以很容易地交换为氘或氚，因此允许合成氘或氚标记的醇、胺和氨基酸。早期发现氰基氢硼酸锂的还原能力 4 和酸稳定性 5 ，并致力于研究改性硼氢化物作为有机官能团的选择性还原剂 。2.3 2127 (1962)；(c) R. 保罗和 N。约瑟夫，布尔。SOC。化学 神父，550 (1952)；(d) HC Brown 和 EJ Mead, J。阿米尔。化学 SOC., 75

  DOI：

  10.1021/ja00741a013

文献信息

• Domino Synthesis of Bridged Bicyclic Tetrahydro-1,2-oxazines: Access to Stereodefined 4-Aminocyclohexanols
  作者：Dwayne A. Dias、Michael A. Kerr

  DOI：10.1021/ol901454y

  日期：2009.8.20

  The intramolecular variant of the homo-[3 + 2]-dipolar cycloaddition of nitrones (generated in situ from an aldehyde and a hydroxylamine) with donor−acceptor cyclopropanes allows for the efficient synthesis of bridged tetrahydro-1,2-oxazines. This domino sequence produces adducts amenable to reductive N−O bond cleavage producing cis-1,4-aminocyclohexanols in excellent yields.

  硝酮的同型[3 + 2]-偶极环加成（从醛和羟胺原位生成）与供体-受体环丙烷的分子内变体可以有效合成桥连的四氢-1，2-恶嗪。该多米诺序列产生适合还原性N-O键裂解的加合物，以优异的产率产生顺式-1,4-氨基环己醇。
• Tissue Factor Production Inhibitor
  申请人：Terasaka Naoki

  公开号：US20080255111A1

  公开（公告）日：2008-10-16

  A medicament which has an activity of inhibiting production of tissue factor and comprises an LXR ligand as an active ingredient; and a medicament for treatment and/or prophylaxis of vascular restenosis following angioplasty, endarterectomy, percutaneous transluminal coronary angioplasty (PTCA) or stent implantation, or treatment and/or prophylaxis of blood coagulation diseases, diseases induced by platelet aggregation including stable or unstable angina pectoris, cardiovascular and cerebrovascular diseases including thromboembolism formation diseases accompanying diabetes, rethrombosis following thrombolysis, cerebral ischemic attack, infarction, stroke, ischemia-derived dementia, peripheral artery disease, thromboembolism formation diseases during use of an aorta-coronary artery bypass, glomerulosclerosis, renal embolism, tumor or cancer metastasis, which comprises an LXR ligand as an active ingredient.

  一种药物，具有抑制组织因子产生活性，包括LXR配体作为活性成分;以及用于治疗和/或预防血管再狭窄的药物，包括血管成形术，动脉内膜切除术，经皮冠状动脉成形术（PTCA）或支架植入术后的治疗和/或预防，或治疗和/或预防血液凝固疾病，包括稳定或不稳定的心绞痛，心血管和脑血管疾病，包括伴随糖尿病的血栓栓塞形成疾病，溶栓后再栓塞，脑缺血发作，梗塞，中风，缺血性痴呆，周围动脉疾病，主动脉冠状动脉旁路使用期间的血栓栓塞形成疾病，肾小球硬化，肾脏栓塞，肿瘤或癌症转移，其中包括LXR配体作为活性成分。
• Benzene Compound Having 2 or More Substituents
  申请人：Tamaki Kazuhiko

  公开号：US20080004301A1

  公开（公告）日：2008-01-03

  A superior LXR modulator is provided. A compound represented by the general formula (I): [wherein R 1 : —COR 9 (wherein R 9 : alkyl, optionally substituted alkoxy or optionally substituted amino); R 2 : H, OH, alkoxy, optionally substituted amino, etc.; R 3 : H, optionally substituted alkyl, cycloalkyl, optionally substituted alkoxy, optionally substituted amino, halogeno, etc.; R 4 and R 5 : H, optionally substituted alkyl, halogeno, etc.; R 6 and R 7 : H, alkyl; R 8 : —X 2 R 10 [wherein R 10 : —COR 11 (wherein R 11 : OH, optionally substituted alkoxy, optionally substituted amino, etc.), —SO 2 R 12 (wherein R 12 : optionally substituted alkyl, optionally substituted amino, etc.), tetrazol-5-yl, etc.; X 2 : single bond, optionally substituted alkylene, etc.]; X 1 : —NH—, —O—, —S—, etc.; Y 1 : optionally substituted phenyl, optionally substituted 5- to 6-membered aromatic heterocyclyl; Y 2 : optionally substituted aryl, optionally substituted heterocyclyl, etc.] and the like is provided.

  提供了一种优越的LXR调节剂。化合物的一般式(I)如下：[其中R1：-COR9（其中R9：烷基，可选地取代的烷氧基或可选地取代的氨基）；R2：H，OH，烷氧基，可选地取代的氨基等；R3：H，可选地取代的烷基，环烷基，可选地取代的烷氧基，可选地取代的氨基，卤素等；R4和R5：H，可选地取代的烷基，卤素等；R6和R7：H，烷基；R8：-X2R10 [其中R10：-COR11（其中R11：OH，可选地取代的烷氧基，可选地取代的氨基等），-SO2R12（其中R12：可选地取代的烷基，可选地取代的氨基等），四唑-5-基等；X2：单键，可选地取代的烷基等]；X1：-NH-，-O-，-S-等；Y1：可选地取代的苯基，可选地取代的5-至6-成员芳香杂环基；Y2：可选地取代的芳基，可选地取代的杂环基等]。
• Synthesis of Phosphinic Amides from Chlorophosphines and Hydroxyl Amines via P(III) to P(V) Rearrangement
  作者：Fang Cheng、Dongqiu Li、Jing Li、Yuhai Tang、Yong Wu、Silong Xu

  DOI：10.1021/acs.orglett.3c00229

  日期：——

  we devised a phosphorus-containing species as a radical precursor, but without the generation of phosphorus waste. Accordingly, a catalyst-free synthesis of phosphinic amides from hydroxyl amines and chlorophosphines via P(III) to P(V) rearrangement is described. Mechanistically, it may involve the initial formation of a R2N–O–PR2 species that undergoes homolysis of N–O bonds and subsequent radical

  膦酰基是产生新自由基的重要介质，但通常会产生化学计量的氧化膦/硫化物废物。在此，我们设计了一种含磷物质作为自由基前体，但不会产生磷废物。因此，描述了通过 P(III) 到 P(V) 重排从羟基胺和氯膦无催化剂合成次膦酰胺。从机理上讲，它可能涉及 R 2 N–O–PR 2物种的初始形成，该物种经历 N–O 键的均裂和随后的自由基重组。
• Method for the synthesis of desferrioxamine B and analogs thereof, and intermediates
  申请人：THE UNIVERSITY OF FLORIDA

  公开号：EP0347163A2

  公开（公告）日：1989-12-20

  Disclosed is a synthesis of desferrioxamine B and analogs and homologs thereof beginning with the generation of the O-protected N-(4-cyanobutyl)hydroxylamine which is acylated at the O-benzylhydroxylamine nitrogen with either succinic or acetic anhydride. The resulting half-acid amide or amide respectively, is subjected to a series of high yield condensations and reductions which provide desferrioxamine B in 45% overall yield. Finally, a desamino analog of desferrioxamine is prepared in order to demonstrate the synthetic utility of the scheme as applied to desferrioxamine derivatives.

  本发明公开了一种去铁胺 B 及其类似物和同系物的合成方法，首先生成 O 保护的 N-(4-氰基丁基)羟胺，然后用丁二酸酐或乙酸酐在 O-苄基羟胺氮上酰化。生成的半酸酰胺或酰胺分别经过一系列高产率的缩合和还原反应，最终得到总产率为 45% 的去铁胺 B。最后，还制备了去铁胺的去氨基类似物，以证明该方案在去铁胺衍生物合成方面的实用性。